Literature DB >> 18520448

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.

Michelle G Goveia1, Mark J DiNubile, Michael J Dallas, Penny M Heaton, Barbara J Kuter.   

Abstract

The efficacy of a live, oral, pentavalent rotavirus vaccine against G1-4 rotavirus gastroenteritis (RVGE) was retrospectively assessed based on breastfeeding frequency among 5098 infants in a placebo-controlled trial. The efficacy against any RVGE severity for infants never breastfed, sometimes breastfed, or exclusively breastfed was 68.3%, 82.2%, and 68.0%, respectively. The efficacy against severe RVGE was 100%, 95.4%, and 100%, respectively. Breastfeeding did not seem to adversely impact the efficacy of pentavalent rotavirus vaccine.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18520448     DOI： 10.1097/INF.0b013e318168d29e

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  19 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

Review 2.  Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries.

Authors:  Katayi Mwila; Roma Chilengi; Michelo Simuyandi; Sallie R Permar; Sylvia Becker-Dreps
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

Review 3.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

4.  Literature Review on Rotavirus: Disease and Vaccine Characteristics: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors:  E L Ford-Jones; S Calvin
Journal:  Can Commun Dis Rep       Date:  2010-11-30

Review 5.  Options for improving effectiveness of rotavirus vaccines in developing countries.

Authors:  Marion S Tissera; Daniel Cowley; Nada Bogdanovic-Sakran; Melanie L Hutton; Dena Lyras; Carl D Kirkwood; Jim P Buttery
Journal:  Hum Vaccin Immunother       Date:  2016-11-11       Impact factor: 3.452

6.  Vaccine-derived NSP2 segment in rotaviruses from vaccinated children with gastroenteritis in Nicaragua.

Authors:  Filemón Bucardo; Christine M Rippinger; Lennart Svensson; John T Patton
Journal:  Infect Genet Evol       Date:  2012-04-02       Impact factor: 3.342

7.  Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.

Authors:  Myron J Levin; Jane C Lindsey; Susan S Kaplan; Werner Schimana; Jody Lawrence; Monica M McNeal; Mutsa Bwakura-Dangarembizi; Anthony Ogwu; Evans M Mpabalwani; Paul Sato; George Siberry; Margaret Nelson; Darcy Hille; Geoffrey A Weinberg; Adriana Weinberg
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

8.  Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries.

Authors:  Sung-Sil Moon; Jacqueline E Tate; Pratima Ray; Penelope H Dennehy; Derseree Archary; Anna Coutsoudis; Ruth Bland; Marie-Louise Newell; Roger I Glass; Umesh Parashar; Baoming Jiang
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

9.  Unexpectedly high burden of rotavirus gastroenteritis in very young infants.

Authors:  H Fred Clark; Amy E Marcello; Diane Lawley; Megan Reilly; Mark J DiNubile
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

10.  The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.

Authors:  Yuxiao Wang; Jingxin Li; Pei Liu; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.